Clinical Trial: Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma

U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07730515) titled 'Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma' on July 08.

Brief Summary: In this study, the XNW5004 tablets combined with CHOP/CHOEP will be used for the treatment of newly diagnosed PTCL patients.

Study Start Date: Aug. 15, 2025

Study Type: INTERVENTIONAL

Condition: Non-hodgkin Lymphoma Peripheral T-cell Lymphoma

Intervention: DRUG: XNW5004 combined with CHOP (incremental)

The XNW5004 protocol has preset four dosage groups: 400mg, 800mg, 1200mg and 1600mg, administered twice daily (BID). The CHOP regimen is administered at a fixed dose, for a total of 6 cycles. A...